BDI Pharma is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The HCA Physician Services Group, a part of the HCA family, is focused on implementing innovative, value-added solutions that help our physicians deliver high quality, cost effective healthcare and support HCA`s commitment to the care and improvement of human life. As the physician solution for HCA, the Physician Services Group makes it easier for physicians to practice medicine by reducing the burdens of managing an independent practice and infusing the best clinical and operational standards in every office. The Physician Services Group is always looking for great people who are passionate about caring for human life. We are looking for experienced health care executives, skilled operators, area and market managers, practice managers, accountants, coders, business analysts, charge entry specialists, medical assistants and all around leaders ready for their next great opportunity.
CONFIDENT SMILE is a Lancaster, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Assil Eye Institute is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.